18. 脊髄小脳変性症（多系統萎縮症を除く。）
［臨床試験数：59，薬物数：78（DrugBank：28），標的遺伝子数：44，標的パスウェイ数：59］
Searched query = "Spinocerebellar degeneration", "SCD", "Spinocerebellar ataxia type I", "SCA1", "Spinocerebellar ataxia type II", "SCA2", "Spinocerebellar ataxia type III", "SCA3", "Machado-Joseph disease", "Spinocerebellar ataxia type VI", "SCA6", "Spinocerebellar ataxia type VII", "SCA7", "Spinocerebellar ataxia type X", "SCA10", "Spinocerebellar ataxia type XII", "SCA12", "Dentatorubural pallidoluysian atrophy", "Dentatorubropallidoluysial atrophy", "DRPLA", "Naito-Koyanagi disease", "Friedreich ataxia", "FRDA", "Ataxia with vitamin E deficiency", "AVED", "Early-onset ataxia with ocular motor ataxia and hypoalbuminemia", "EOAH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02889302 (ClinicalTrials.gov) | November 15, 2016 | 31/8/2016 | An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | An Additional Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | All | 203 | Phase 3 | Japan |
| 2 | NCT01970098 (ClinicalTrials.gov) | October 9, 2013 | 22/10/2013 | A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | A Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | All | 374 | Phase 3 | Japan |
| 3 | NCT01970137 (ClinicalTrials.gov) | October 2013 | 22/10/2013 | A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | Phase 3 | Japan | ||
| 4 | NCT01970111 (ClinicalTrials.gov) | October 2013 | 22/10/2013 | An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | Phase 3 | Japan | ||
| 5 | NCT01970124 (ClinicalTrials.gov) | October 2013 | 22/10/2013 | A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | Phase 3 | Japan | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT01384435 (ClinicalTrials.gov) | June 2011 | 23/6/2011 | A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | A Randomized, Double Blind, Placebo-controlled Phase II Study of KPS-0373 in Patients With SCD | SCD | Drug: KPS-0373;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | 200 | Phase 2 | Japan |
| 7 | NCT01004016 (ClinicalTrials.gov) | October 2009 | 27/10/2009 | A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | A Double-blind, Placebo-controlled, Crossover Study, Followed by Open-label Study of KPS-0373 in Patients With SCD | Spinocerebellar Degeneration | Drug: KPS-0373;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | 20 | Phase 2 | Japan |
| 8 | NCT00863538 (ClinicalTrials.gov) | November 2004 | 16/3/2009 | Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | An Open-label, Phase II Study of KPS-0373 in Patients With SCD | Spinocerebellar Degeneration | Drug: KPS-0373 | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | 40 | Phase 2 | Japan |